Clinerion Ltd Contact Details:
Main address: Margarethenstrasse 47 4053 Basel, Switzerland ,
Tel:+41 61 865 60 60 , E-mail: info(at) Website:

Clinerion Patient Network Explorer

Clinerion Patient Network Explorer

Optimized study design, precise site selection and faster patient search and identification for clinical research - in real time.

Clinerion Cookie Policy

Welcome to the Clinerion website. This website uses cookies. These cookies are used on your browser to understand how you are using our website. Using this website means you agree to our use of cookies. If you prefer not to have these cookies on your device, we advise you to disable them in your web browser settings. You accept the use of cookies by accepting this notice. You can read more details via our Privacy Policy page.

Privacy Policy page >

Real World Analytics

Clinerion’s Patient Network Explorer offers indication-agnostic access to live, real-world, de-identified, aggregate EMR data of its partner hospitals.

Patient Population Analytics Reports

Patient Population Analytics:
Multiple Myeloma in Türkiye

Patient Population Analytics:
Asthma, FeNO ≥20 ppb in the UAE


Extract: Multiple Myeloma in Türkiye

In this example, the Patient Network Explorer was used to develop multiple myeloma Charlson comorbidity scores and co-treatment regime models.

Identified patients in Türkiye with multiple myeloma with first diagnosis in 2018 were evaluated on:

Query Date:


Query Type:

  • ICD10: C90.0
  • Multiple myeloma
  • First diagnosis in 2018

Sample Size:

1,330 patients matching query

Country incidence 2018:


5-year prevalence:

5,432 Patients (prop. 6,63)

# of Clinics:


Clinic Types:

Teaching Hospitals

Total Patients:


Türkiye 2018 population:


Figure 1: Patient demographics in multiple myeloma-identified 2018-first-instance Patient Network Explorer patients  in Clinerion's hosptial network in Türkiye.

At baseline event (first diagnosis with multiple myeloma):

Patients ≤65 years

Patients 65–75 years

Patients >75 years




Median Age

Standard Deviation




Figure 2: Charlson Comorbidity Index scores for multiple myeloma-identified 2018-first-instance Patient Network Explorer patients in Türkiye in Clinerion's hospital network.

Charleson Score # of patients

1 point

2 points

3 points

4 points

5 points

6 points

7 points

8 points

9 points

10 points

11 points

12 points

14 points















Figure 3. Bortezomib treatment regimens in multiple myeloma-identified 2018-first-instance Patient Network Explorer patients in Türkiye in Clinerion's hospital network.

Download these two reports and let us know how we can help.


Personal Data Protection Statement

The information you provide allows us to provide you with information and updates on Clinerion’s products and services (the purpose). By submitting your details in the registration form, you give explicit consent that your personal details may be used for this and only this purpose by Clinerion and webinar partners, who may also provide you with information and updates on their products and services.

Clinerion, as the data controller and processor, will maintain the data for as long as the data is required for the purposes mentioned above, or until you withdraw consent as stated below. Personal data are not kept longer than necessary and are processed in a manner that ensures appropriate security and confidentiality, including for preventing unauthorized access to or use of personal data and the equipment used for the processing.

We will not sell or give away any personal information that you provide and only use it for the purposes stated above. You may request to view, correct, or delete your data in Clinerion’s database or withdraw consent by contacting Please note that withdrawal of consent shall not affect the lawfulness of Clinerion’s use of your personal data for the purposes mentioned above before withdrawal of consent.

The legal address of Clinerion: Clinerion Ltd, Elisabethenanlage 11, 4051 Basel, Switzerland. e-Mail address

News / Events / Webinars